These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17539749)

  • 21. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A benefit-risk assessment of extended-release oxybutynin.
    Michel MC
    Drug Saf; 2002; 25(12):867-76. PubMed ID: 12241127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ
    Urol Nurs; 2010; 30(4):253-4. PubMed ID: 20949812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Low Urin Tract Symptoms; 2016 Sep; 8(3):150-8. PubMed ID: 27619779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of intravesical and oral oxybutynin chloride.
    Massad CA; Kogan BA; Trigo-Rocha FE
    J Urol; 1992 Aug; 148(2 Pt 2):595-7. PubMed ID: 1640530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In brief: Oxytrol OTC.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):76. PubMed ID: 24662958
    [No Abstract]   [Full Text] [Related]  

  • 32. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
    Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
    J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.
    Dmochowski RR; Nitti V; Staskin D; Luber K; Appell R; Davila GW
    World J Urol; 2005 Sep; 23(4):263-70. PubMed ID: 16151816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical oxybutynin (Gelnique) for overactive bladder.
    Med Lett Drugs Ther; 2010 Feb; 52(1331):10-1. PubMed ID: 20216524
    [No Abstract]   [Full Text] [Related]  

  • 38. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome.
    Sheng Y; Zhang S; Ling J; Hu C; Zhang Z; Lv H
    Pharm Dev Technol; 2022 Apr; 27(4):459-468. PubMed ID: 35575444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder.
    Rajabalaya R; David SR; Chellian J; Xin Yun G; Chakravarthi S
    Drug Deliv; 2016 Jun; 23(5):1578-87. PubMed ID: 26634274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.